{"uid":"cap_T4T_jAvF4KJ3jiNI9mXpg","slug":"clinicalintelpulse-pipeline-scan-a5eb7c01","name":"ClinicalIntelPulse Pipeline Scan","description":"Clinical trial pipeline scan for any disease — all active Phase 2/3 trials with trial counts, sponsor landscape, geographic distribution, mechanism breakdown and pipeline density, across 400,000+ trials worldwide. For biotech-investing and pharma agents.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"phase":{"type":"string"},"status":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"condition":"Non-Small Cell Lung Cancer","status_filter":"RECRUITING,ACTIVE_NOT_RECRUITING","phases_searched":["PHASE2","PHASE3"]},"pipeline_totals":{"phase2_count":156,"phase3_count":89,"total_active":245},"phase3_highlights":[{"nctId":"NCT05116748","title":"Pembrolizumab + Carboplatin vs SOC in NSCLC","status":"RECRUITING","sponsor":"Merck","countries":["United States","Germany","Japan","South Korea"],"primaryCompletion":"2026-03"}],"sponsor_landscape":{"academic_sponsors":"ECOG-ACRIN, Alliance, NCI leading academic cooperative groups","emerging_biotechs":["Turning Point Therapeutics","Blueprint Medicines","Mirati Therapeutics"],"top_industry_sponsors":["Roche/Genentech (18 trials)","Bristol-Myers Squibb (14)","AstraZeneca (13)","Merck (12)","Pfizer (11)"]},"mechanism_breakdown":{"adc":18,"other":81,"bispecific":12,"targeted_therapy":41,"chemo_combinations":31,"io_checkpoint_inhibitors":62},"pipeline_assessment":"Extremely crowded pipeline — PD-1/L1 space saturated. ADCs and bispecifics represent highest differentiation potential. KRAS G12C targeted therapies emerging as new standard.","approved_drugs_context":"NSCLC has 30+ FDA-approved agents. Pipeline is additive rather than disruptive in most cases.","geographic_distribution":{"asia_pct":22,"other_pct":5,"europe_pct":28,"us_trials_pct":45,"most_active_countries":["United States","China","Germany","South Korea","Japan"]}}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.15","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.15/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_Q-st_7Sm8iQkgwNA9wTLo","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.15","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Scans the global clinical trial pipeline for any disease, returning active Phase 2/3 trial counts, sponsor landscape, geographic distribution, mechanism breakdown, and pipeline density across 400,000+ trials.","exampleAgentPrompt":"Run a full clinical trial pipeline scan for non-alcoholic steatohepatitis — I want to see all active Phase 2 and Phase 3 trials, the sponsor landscape, which mechanisms are being tested, and how geographically spread the activity is.","exampleUseCases":null,"resultDescription":"Returns an aggregated pipeline report including: total count of active Phase 2/3 trials for the queried disease, list of sponsors and their trial counts, geographic distribution by country/region, breakdown of drug mechanisms of action under investigation, and an overall pipeline density score — drawn from a database of 400,000+ global trials.","failureModes":["Unknown or misspelled disease name returns empty results or a 400 error","Very rare diseases with minimal trial activity return sparse data","Network timeout on large disease areas with thousands of trials","402 Payment Required if USDC payment is not included or insufficient","Rate limiting if called too frequently in succession"],"whenToPreferThis":"Use this endpoint when you need a broad, high-level pipeline overview for a disease area — covering trial volume, sponsor competitive landscape, mechanism diversity, and geographic spread all in one call. Prefer this over single-trial deep-dive endpoints when the goal is strategic intelligence for biotech investing, competitive benchmarking, or pharma market analysis rather than details on a specific trial.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T06:41:02.096Z","isFirstParty":false}